Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Issue 1 (January 1972)

• Record Type: Journal Article
• Authors: Acocella, G.; Bonollo, L.; Garimoldi, M.; Mainardi, M.; Tenconi, L. T.; Nicolis, F. B.
• Is Part Of: Gut. Volume 13:Issue 1(1972)
• Page Start: 47
• Page End: 53
• Publication Date: 1972-01
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gut.13.1.47
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : The possible existence of kinetic interactions between rifampicin and isoniazid and the effect of the concomitant presence of an impaired liver function were investigated in man. In a first study normal healthy subjects and patients with chronic liver disease received, on three different occasions, a single dose of 600 mg rifampicin or isoniazid and of rifampicin and isoniazid associated in randomized sequences. The results have shown that in both groups the serum levels, half-life values, and urinary excretion of each drug given alone are not significantly different from those observed when the other drug is associated. Serum levels and half-life of rifampicin and isoniazid were significantly higher in patients with chronically impaired liver. In a second study, rifampicin and isoniazid were given in combination at the same doses as in the first study over a period of one week. The results have shown a trend to decrease in the serum levels of rifampicin of the healthy subjects and a trend to increase in the patients with chronic liver disease on day 7 of treatment. In both groups a reduction in the half-life of rifampicin was also observed. No changes in serum isoniazid concentrations were observed between day 1 and day 7 in the healthy subjects, whereas a significant increase was observed in the patients. No significant changes in the half-life of isoniazid were observed.